Cargando…

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotani, Daisuke, Oki, Eiji, Nakamura, Yoshiaki, Yukami, Hiroki, Mishima, Saori, Bando, Hideaki, Shirasu, Hiromichi, Yamazaki, Kentaro, Watanabe, Jun, Kotaka, Masahito, Hirata, Keiji, Akazawa, Naoya, Kataoka, Kozo, Sharma, Shruti, Aushev, Vasily N., Aleshin, Alexey, Misumi, Toshihiro, Taniguchi, Hiroya, Takemasa, Ichiro, Kato, Takeshi, Mori, Masaki, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873552/
https://www.ncbi.nlm.nih.gov/pubmed/36646802
http://dx.doi.org/10.1038/s41591-022-02115-4
_version_ 1784877622420832256
author Kotani, Daisuke
Oki, Eiji
Nakamura, Yoshiaki
Yukami, Hiroki
Mishima, Saori
Bando, Hideaki
Shirasu, Hiromichi
Yamazaki, Kentaro
Watanabe, Jun
Kotaka, Masahito
Hirata, Keiji
Akazawa, Naoya
Kataoka, Kozo
Sharma, Shruti
Aushev, Vasily N.
Aleshin, Alexey
Misumi, Toshihiro
Taniguchi, Hiroya
Takemasa, Ichiro
Kato, Takeshi
Mori, Masaki
Yoshino, Takayuki
author_facet Kotani, Daisuke
Oki, Eiji
Nakamura, Yoshiaki
Yukami, Hiroki
Mishima, Saori
Bando, Hideaki
Shirasu, Hiromichi
Yamazaki, Kentaro
Watanabe, Jun
Kotaka, Masahito
Hirata, Keiji
Akazawa, Naoya
Kataoka, Kozo
Sharma, Shruti
Aushev, Vasily N.
Aleshin, Alexey
Misumi, Toshihiro
Taniguchi, Hiroya
Takemasa, Ichiro
Kato, Takeshi
Mori, Masaki
Yoshino, Takayuki
author_sort Kotani, Daisuke
collection PubMed
description Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm of the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical and postsurgical ctDNA in patients with stage II–IV resectable CRC (n = 1,039). In this cohort, with a median follow-up of 16.74 months (range 0.49–24.83 months), postsurgical ctDNA positivity (at 4 weeks after surgery) was associated with higher recurrence risk (hazard ratio (HR) 10.0, P < 0.0001) and was the most significant prognostic factor associated with recurrence risk in patients with stage II or III CRC (HR 10.82, P < 0.001). Furthermore, postsurgical ctDNA positivity identified patients with stage II or III CRC who derived benefit from ACT (HR 6.59, P < 0.0001). The results of our study, a large and comprehensive prospective analysis of ctDNA in resectable CRC, support the use of ctDNA testing to identify patients who are at increased risk of recurrence and are likely to benefit from ACT.
format Online
Article
Text
id pubmed-9873552
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-98735522023-01-26 Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer Kotani, Daisuke Oki, Eiji Nakamura, Yoshiaki Yukami, Hiroki Mishima, Saori Bando, Hideaki Shirasu, Hiromichi Yamazaki, Kentaro Watanabe, Jun Kotaka, Masahito Hirata, Keiji Akazawa, Naoya Kataoka, Kozo Sharma, Shruti Aushev, Vasily N. Aleshin, Alexey Misumi, Toshihiro Taniguchi, Hiroya Takemasa, Ichiro Kato, Takeshi Mori, Masaki Yoshino, Takayuki Nat Med Article Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm of the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical and postsurgical ctDNA in patients with stage II–IV resectable CRC (n = 1,039). In this cohort, with a median follow-up of 16.74 months (range 0.49–24.83 months), postsurgical ctDNA positivity (at 4 weeks after surgery) was associated with higher recurrence risk (hazard ratio (HR) 10.0, P < 0.0001) and was the most significant prognostic factor associated with recurrence risk in patients with stage II or III CRC (HR 10.82, P < 0.001). Furthermore, postsurgical ctDNA positivity identified patients with stage II or III CRC who derived benefit from ACT (HR 6.59, P < 0.0001). The results of our study, a large and comprehensive prospective analysis of ctDNA in resectable CRC, support the use of ctDNA testing to identify patients who are at increased risk of recurrence and are likely to benefit from ACT. Nature Publishing Group US 2023-01-16 2023 /pmc/articles/PMC9873552/ /pubmed/36646802 http://dx.doi.org/10.1038/s41591-022-02115-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kotani, Daisuke
Oki, Eiji
Nakamura, Yoshiaki
Yukami, Hiroki
Mishima, Saori
Bando, Hideaki
Shirasu, Hiromichi
Yamazaki, Kentaro
Watanabe, Jun
Kotaka, Masahito
Hirata, Keiji
Akazawa, Naoya
Kataoka, Kozo
Sharma, Shruti
Aushev, Vasily N.
Aleshin, Alexey
Misumi, Toshihiro
Taniguchi, Hiroya
Takemasa, Ichiro
Kato, Takeshi
Mori, Masaki
Yoshino, Takayuki
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
title Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
title_full Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
title_fullStr Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
title_full_unstemmed Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
title_short Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
title_sort molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873552/
https://www.ncbi.nlm.nih.gov/pubmed/36646802
http://dx.doi.org/10.1038/s41591-022-02115-4
work_keys_str_mv AT kotanidaisuke molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT okieiji molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT nakamurayoshiaki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT yukamihiroki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT mishimasaori molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT bandohideaki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT shirasuhiromichi molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT yamazakikentaro molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT watanabejun molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT kotakamasahito molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT hiratakeiji molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT akazawanaoya molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT kataokakozo molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT sharmashruti molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT aushevvasilyn molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT aleshinalexey molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT misumitoshihiro molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT taniguchihiroya molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT takemasaichiro molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT katotakeshi molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT morimasaki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer
AT yoshinotakayuki molecularresidualdiseaseandefficacyofadjuvantchemotherapyinpatientswithcolorectalcancer